May 3, 2023 Building a Corporate Responsibility Program from the Ground Up: Key Learnings from Alnylam ... If you are building your program or assessing your program, here are five key learnings which may be helpful to your organization Read More ›
December 8, 2022 Alnylam Named One of America's Most Responsible Companies by Newsweek Alnylam has been named one of America's Most Responsible Companies for 2023 by Newsweek and research firm Statista Read More ›
June 20, 2022 Challenging Ourselves to Help Refugees: Supporting Refugees to Become Work-Ready Alnylam has announced a three-year corporate partnership with Refugee Action, a United Kingdom (UK)-based charity dedicated to helping refugees... Read More ›
March 16, 2022 Alnylam Publishes 2021 Corporate Responsibility Report We're committed to taking bold actions that improve the health of humanity. Our 2021 Corporate Responsibility Report provides details on our progress... Read More ›
October 13, 2021 Alnylam Challengers - a Health Equity Community Impact Program Alnylam Challengers is Alnylam's signature CSR Community Impact Program. It aims to improve health access to underserved communities. Read More ›
March 11, 2021 Alnylam Publishes First Corporate Responsibility Summary Today, we've published Alnylam's first Corporate Responsibility Summary detailing our approach to corporate responsibility and the actions we are and intend... Read More ›
March 29, 2019 Team Alnylam Hits the Court to Support Massachusetts Special Olympics Alnylam joined more than a dozen biotech companies in the annual Bioball Basketball Tournament to support the Massachusetts Special Olympics. Read More ›

Get In Touch

Have any questions or comments about the content you see on this page?

You are now leaving

The following content may not be associated with Alnylam Pharmaceuticals.

Links to all outside sites are provided as a reference for our visitors.

Alnylam Pharmaceuticals does not endorse and is not responsible for the content on sites that are not owned and operated by Alnylam Pharmaceuticals.

Proceed to Site